Core Viewpoint - SUNation Energy Inc. announced a final cash distribution of $0.12 per non-transferable Contingent Value Right (CVR) to its holders, fulfilling its payment obligations and simplifying its capital structure [1][2]. Group 1: Final Distribution Details - The total final payment amounts to $276,000.48, which will be distributed to all CVR holders starting on or about December 5, 2025 [2]. - Following this payment, the Contingent Value Rights Agreement will terminate, and the CVRs will expire without any further compensation [2]. Group 2: Company Operations and Strategy - SUNation Energy focuses on providing sustainable solar energy and backup power solutions to households, businesses, and municipalities, and aims to grow its presence in the solar and energy services market [1][4]. - The company has made significant operational improvements over the past two years, including cost reductions, debt elimination, and enhanced efficiencies while maintaining high customer service levels [2].

Core Viewpoint - Quantum BioPharma Ltd. announces the expiration of 53,147 warrants and reiterates the record date for the distribution of contingent value rights (CVRs) to shareholders, linked to ongoing litigation against financial institutions for alleged stock price manipulation [1][2][3]. Group 1: Warrants Expiration - The company has expired 53,147 warrants, which were part of a previous financing completed on October 20, 2020, and represents the last tranche issued to hedge funds and investment funds [1]. - The original number of warrants issued was 3,454,543 before a reverse stock split of 65 to 1 [1]. Group 2: Contingent Value Rights (CVRs) - The record date for the distribution of CVRs is set for October 27, 2025, on a one-for-one basis for holders of Class B Subordinate Voting Shares [2]. - Each CVR will entitle holders to a pro rata portion of a minimum of 10% and up to 50% of the net proceeds from the company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million [3][4]. - Payments under the CVRs will only occur if the company receives net proceeds from the litigation, and there is no guarantee that any proceeds will be received [5][8]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various stages of development [6]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key mechanism in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of health products, and has a royalty agreement that provides 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [6].